Immuno inhibitory heterocyclic compounds
US7566713B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 26, 2005 |
| Grant date | Jul 28, 2009 |
| Priority date | — |
| Expiry date | Apr 26, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of formula (I) are CD80 inhibitors, and of value for immunomodulation, e.g. in rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis: wherein Y is —CH2—, —CH2CH2—, or CH2CH2CH2—; R1 represents H; F; methyl, trifuoromethyl, methoxy or triflioromethoxy; R3 represents H; F; CI; Br; NO2; CN; C1C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O) NR6R7—NR7C(═O)R6, NR7C(═O)OR6, NHC(═O) or NHC(═S)NR7R6 wherein R6 and R7 are as defined in the specification and X represents a bond or a divalent radical as defined in the specification.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.